Abstract
Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. The primary outcome was PFS as assessed by the investigator; ...Continue Reading
References
May 1, 2004·The New England Journal of Medicine·Thomas J LynchDaniel A Haber
May 1, 2004·Science·J Guillermo PaezMatthew Meyerson
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstAlan Sandler
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramaswamy GovindanJay Piccirillo
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Sep 1, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN Participating Institutions
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George N NaumovJohn V Heymach
Jun 6, 2009·Cancer Research·Eiki IchiharaKatsuyuki Kiura
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 21, 2009·The New England Journal of Medicine·Rafael RosellUNKNOWN Spanish Lung Cancer Group
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiWallace Akerley
Jul 24, 2010·The Lancet Oncology·Lucio CrinòCaicun Zhou
Jan 20, 2011·British Journal of Cancer·N B LeighlH Hurwitz
May 31, 2011·Lancet·Roy S HerbstJohn Hainsworth
Jul 26, 2011·The Lancet Oncology·Caicun ZhouChangxuan You
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pasi A JänneVincent A Miller
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jan 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardPasi A Jänne
May 23, 2014·JAMA : the Journal of the American Medical Association·Mark G KrisPaul A Bunn
Sep 2, 2014·The Lancet Oncology·Takashi SetoNobuyuki Yamamoto
Oct 27, 2014·Cancer Chemotherapy and Pharmacology·Heyan LiYoichi Nakanishi
Jan 16, 2015·The Lancet Oncology·James Chih-Hsin YangLecia V Sequist
Jan 19, 2016·Lancet·Fabrice BarlesiUNKNOWN Biomarkers France contributors
Apr 15, 2017·The Lancet. Respiratory Medicine·Rafael RosellUNKNOWN BELIEF collaborative group
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Citations
Mar 3, 2020·Journal of Drug Targeting·Rui LiLiang Li
Jun 13, 2020·Expert Review of Anticancer Therapy·Giulia SartoriSara Pilotto
Sep 2, 2020·Future Oncology·MeganS FarrisJasmina I Ivanova
Jul 28, 2020·Frontiers in Oncology·Fei ChenJiuwei Cui
Apr 3, 2020·Expert Review of Respiratory Medicine·Simona Scodes, Federico Cappuzzo
Sep 19, 2020·Current Oncology Reports·Monica PeravaliIrina Veytsman
Sep 10, 2020·OncoTargets and Therapy·Hui Xu, Chuan Shao
Jul 8, 2020·Journal of Cancer Research and Clinical Oncology·Thierry LandreChristos Chouaid
Oct 18, 2020·Clinical Lung Cancer·Zhujun DengYou Lu
Jan 8, 2021·JAMA Oncology·Hiroaki AkamatsuNobuyuki Yamamoto
Oct 24, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Xiuning LeEdward B Garon
Jan 26, 2021·Heliyon·Ana Salomé CorreiaNuno Vale
Feb 13, 2021·BioMed Research International·Jie-Tao MaCheng-Bo Han
Dec 22, 2020·JNCI Cancer Spectrum·Fabio ConfortiTommaso De Pas
Mar 10, 2021·Current Medical Research and Opinion·Soham ShuklaLuigi Brunetti
Dec 16, 2020·Clinical Lung Cancer·Xiang-Meng LiJin-Ji Yang
Apr 28, 2021·Cancer Treatment and Research Communications·S Ponce AixUNKNOWN RELAY investigators
Apr 19, 2021·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Jeng-Shiuan TsaiWu-Chou Su
May 18, 2021·Therapeutic Advances in Medical Oncology·Wolfgang M BrücklEckart Laack
May 26, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hongyun ZhaoLi Zhang
Jul 3, 2021·Cancers·Karam KhaddourYanis Boumber
Jul 13, 2021·Clinical Lung Cancer·Shuang ZhangYing Cheng
Jun 14, 2021·Critical Reviews in Oncology/hematology·Yuzhong ChenBo Shen
Aug 14, 2021·Cancer Cell·Xiuning LeJohn V Heymach
Aug 25, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Bin-Chi Liao, James Chih-Hsin Yang
Nov 24, 2021·Current Opinion in Oncology·Chiara LazzariVanesa Gregorc
Dec 8, 2021·Signal Transduction and Targeted Therapy·Susanne Hafner